In addition, 10 further cases were classified as AML with mutated NPM1 (according to WHO 2017: AML-MRC: n = 4; MDS-EB-2: n = 4; MDS-EB-1: n = 1; MDS-MLD: n = 1) and 5 cases as AML with mutated CEBPA (former AML-MRC due to the superior hierarchical status of a previously documented MDS or MDS/MPN history or showing MR cytogenetic abnormalities in the WHO 2017). This evidence concerns the gene NPM1 and acute myeloid leukemia.